Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

873 - A pooled analysis evaluating the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk


10 Sep 2017


Poster display session


Mototsugu Shimokawa


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


M. Shimokawa1, T. Kogawa2, J. Nishimura3, T. Satoh4, K. Nakata5, T. Hayashi6, R. Matsui7, K. Aiba8, K. Tamura9

Author affiliations

  • 1 Clinical Research Institute, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 2 Department Of Developmental Therapeutics, National Cancer Center Hospital East, Kashiwa/JP
  • 3 Department Of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita/JP
  • 4 Department Of Frontier Science For Cancer And Chemotherapy, Graduate School of Medicine, Osaka University, Suita/JP
  • 5 Department Of Surgery, Sakai city medical center, Sakai/JP
  • 6 Department Of Pharmacy, National Kyushu Medical Center, Fukuoka/JP
  • 7 Department Of Pharmacy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 8 Division Of Clinical Oncology/hematology, The Jikei University School of Medicine, 105-8461 - Tokyo/JP
  • 9 General Medical Research Center, Fukuoka University, Fukuoka/JP


Abstract 873


The incidence and risk factor of delayed chemotherapy-induced nausea and vomiting (CINV) for colorectal cancer (CRC) patients receiving oxaliplatin-based chemotherapy has not been clearly controlled. To evaluate the efficacy and risk factor of combination antiemetic treatment for delayed CINV in CRC patients receiving oxaliplatin-based chemotherapy.


Aggregated data were pooled from the two prospective observational studies and one clinical trial; A nationwide survey of CINV study group, the other prospective observational study in Japan and SENRI Trial in Japan. We assessed whether delayed CINV were controlled with 3 antiemetic treatment. We also evaluated risk factors by logistic regression analysis.


A total of 661 patients were evaluable in this study. The median age was 64 (range:19-85) with 391males and 270 females. Three antiemetics were used in 220 (33.3%) patients. Delayed CINV were experienced more commonly in women than in men. Delayed nausea was well controlled with 3 antiemetics than with 2 antiemetics for women (38.3% vs. 52.8%; P=0.0295). Delayed vomiting was well controlled with 3 antiemetics than with 2 antiemetics for overall (4.1% vs. 15.9%; P


Three antiemetics combination are encouraged for CRC female patients treated with oxaliplatin-based chemotherapy to alleviate delayed CINV. Identification of individual risk factors will assist in the development of personalized treatments for delayed CINV.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.